A long-awaited HIV treatment, designed specifically for children, is available now at much lower cost in low-and middle-income countries, thanks to a recent agreement between the Clinton Health Access Initiative (CHAI) and Unitaid.
Only half of the almost two million children living with HIV around the world receive any treatment and 100,000 of them die every year, due to the lack of effective drugs that are palatable and properly adapted for them.
An agreement brokered by Unitaid and CHAI with generic manufacturers Viatris and Macleods reduces the price of a new dispersible formulation of the recommended first-line HIV treatment dolutegravir (DTG) from $400 to $36 per child per year.
i+solutions has been contracted by CHAI to coordinate with the suppliers on the pre-shipment testing and delivery of the product to 6 countries: Benin, Kenya, Malawi, Nigeria, Uganda and Zimbabwe. Pre shipment testing and delivery involves sending product samples to a quality control lab to ensure the product meets the standards as per the tentative FDA approval. For the delivery, we will be using our normal portfolio of pre-qualified logistic service providers. The first shipments are scheduled for the first quarter of 2021.
We are proud to be part of this mission and consider it an acknowledgement of our expertise!
Please read the full article here Ground-breaking agreement reduces by 75% the cost of HIV treatment for children in low-and middle-income countries
